Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tom Taghon

Showing results (61-70 of 135) with videos related to

Pageof 14
Sort By:
Frontiers in Immunology|November 29, 2016
The Ly49E Receptor Inhibits the Immune Control of Acute <i>Trypanosoma cruzi</i> InfectionJessica Filtjens, Nicolas Coltel, Sabrina Cencig, et al.
The Journal of Experimental Medicine|August 24, 2016
NKT sublineage specification and survival requires the ubiquitin-modifying enzyme TNFAIP3/A20Michael B Drennan, Srinath Govindarajan, Eveline Verheugen, et al.
Journal of Leukocyte Biology|April 14, 2011
Langerhans cells are not required for epidermal Vgamma3 T cell homeostasis and functionSylvie Taveirne, Veerle De Colvenaer, Tina Van Den Broeck, et al.
Plos One|February 6, 2014
Contribution of the Ly49E natural killer receptor in the immune response to Plasmodium berghei infection and control of hepatic parasite developmentJessica Filtjens, Lander Foquet, Sylvie Taveirne, et al.
Blood|September 12, 2008
Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activatorTina Van Den Broeck, Frederik Stevenaert, Sylvie Taveirne, et al.
Science Translational Medicine|May 31, 2019
Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibitionRoger A Habets, Charles E de Bock, Lutgarde Serneels, et al.
Haematologica|April 26, 2012
RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemiaSylvia Snauwaert, Stijn Vanhee, Glenn Goetgeluk, et al.
Oncoimmunology|April 14, 2017
Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacitiesYasmine Van Caeneghem, Stijn De Munter, Paola Tieppo, et al.
Frontiers in Immunology|October 11, 2021
T-BET and EOMES Accelerate and Enhance Functional Differentiation of Human Natural Killer CellsLaura Kiekens, Wouter Van Loocke, Sylvie Taveirne, et al.
International Journal of Molecular Sciences|November 25, 2020
Human Thymic CD10<sup>+</sup> PD-1<sup>+</sup> Intraepithelial Lymphocyte Precursors Acquire Interleukin-15 Responsiveness at the CD1a<sup>-</sup> CD95<sup>+</sup> CD28<sup>-</sup> CCR7<sup>-</sup> Developmental StageLore Billiet, Glenn Goetgeluk, Sarah Bonte, et al.
Pageof 14

Showing results (61-70 of 135) with videos related to

Sort By:
Pageof 14
Frontiers in Immunology|November 29, 2016
The Ly49E Receptor Inhibits the Immune Control of Acute <i>Trypanosoma cruzi</i> InfectionJessica Filtjens, Nicolas Coltel, Sabrina Cencig, et al.
The Journal of Experimental Medicine|August 24, 2016
NKT sublineage specification and survival requires the ubiquitin-modifying enzyme TNFAIP3/A20Michael B Drennan, Srinath Govindarajan, Eveline Verheugen, et al.
Journal of Leukocyte Biology|April 14, 2011
Langerhans cells are not required for epidermal Vgamma3 T cell homeostasis and functionSylvie Taveirne, Veerle De Colvenaer, Tina Van Den Broeck, et al.
Plos One|February 6, 2014
Contribution of the Ly49E natural killer receptor in the immune response to Plasmodium berghei infection and control of hepatic parasite developmentJessica Filtjens, Lander Foquet, Sylvie Taveirne, et al.
Blood|September 12, 2008
Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activatorTina Van Den Broeck, Frederik Stevenaert, Sylvie Taveirne, et al.
Science Translational Medicine|May 31, 2019
Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibitionRoger A Habets, Charles E de Bock, Lutgarde Serneels, et al.
Haematologica|April 26, 2012
RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemiaSylvia Snauwaert, Stijn Vanhee, Glenn Goetgeluk, et al.
Oncoimmunology|April 14, 2017
Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacitiesYasmine Van Caeneghem, Stijn De Munter, Paola Tieppo, et al.
Frontiers in Immunology|October 11, 2021
T-BET and EOMES Accelerate and Enhance Functional Differentiation of Human Natural Killer CellsLaura Kiekens, Wouter Van Loocke, Sylvie Taveirne, et al.
International Journal of Molecular Sciences|November 25, 2020
Human Thymic CD10<sup>+</sup> PD-1<sup>+</sup> Intraepithelial Lymphocyte Precursors Acquire Interleukin-15 Responsiveness at the CD1a<sup>-</sup> CD95<sup>+</sup> CD28<sup>-</sup> CCR7<sup>-</sup> Developmental StageLore Billiet, Glenn Goetgeluk, Sarah Bonte, et al.
Pageof 14